2024
Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road
Ríos-Hoyo A, Monzonís X, Vidal J, Linares J, Montagut C. Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. Frontiers In Pharmacology 2024, 15: 1398419. PMID: 38711991, PMCID: PMC11070789, DOI: 10.3389/fphar.2024.1398419.Peer-Reviewed Original ResearchAnti-EGFR therapyResistance to anti-EGFR therapySecondary resistance to anti-EGFR therapiesColorectal cancerEmergence of acquired resistanceExtracellular domain of EGFRMetastatic colorectal cancerBlood of patientsClinical cohort studyDomain of EGFRMulti-drug treatmentBenefits of rechallengeEGFR blockadePotential therapeutic strategyAnti-EGFRClinical benefitTumor cellsGenomic alterationsLiquid biopsyCohort studyClinical trialsTherapeutic strategiesTherapyPatientsRechallenge
2023
Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic
Rios-Hoyo A, Arriola E. Immunotherapy and brain metastasis in lung cancer: connecting bench side science to the clinic. Frontiers In Immunology 2023, 14: 1221097. PMID: 37876939, PMCID: PMC10590916, DOI: 10.3389/fimmu.2023.1221097.Peer-Reviewed Original ResearchConceptsBrain metastasesCell lung cancerLung cancerTumor cellsTreatment strategiesAnti-CTLA-4 antibodyManagement of brain metastasesPD-1/PD-L1 axisNon-small cell lung cancerSmall cell lung cancerBrain parenchymaEra of immunotherapyIntracranial malignant neoplasmsSequence of immunotherapySymptomatic brain metastasesImmune checkpoint inhibitorsPD-1/PD-L1Extravasation of tumor cellsTreatment of BMBlood-brain barrierCheckpoint inhibitorsDismal prognosisImmune cellsLocal invasionProtumor effects